Mereo BioPharma
Entering an important 12 month periodMereo BioPharma
Accelerated approval path for NAVIMereo BioPharma
Encouraging interim BPS-804 data in OIMereo BioPharma
Focus shifts back to imminent dataMereo BioPharma
Path cleared for partnering of acumapimod (BCT-197)Mereo BioPharma
Executing a well articulated strategyMereo BioPharma
Merger with NASDAQ-listed OncoMedMereo BioPharma
Phase II starts with backing from patient support groupMereo BioPharma
Raring to go in rare diseases